Quick Answer
Orchestra BioMed Holdings, Inc. reported Cash and Equivalents of $34.69 million for fiscal year 2025.
Orchestra BioMed Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $34.69M | +55.8% |
| 2024 | $22.26M | -27.2% |
| 2023 | $30.56M | +54.5% |
| 2022 | $19.78M | +1027.6% |
| 2021 | $1.75M | -13.4% |
| 2020 | $2.03M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $42.01M | +64.1% | +124.1% |
| June 30, 2025 | $18.75M | -20.9% | +2.2% |
| March 31, 2025 | $18.35M | -21.3% | -17.6% |
| December 31, 2024 | $22.26M | -27.2% | -13.1% |
| September 30, 2024 | $25.61M | +34.2% | +8.0% |
| June 30, 2024 | $23.71M | +44.5% | +1.7% |
| March 31, 2024 | $23.32M | +24.8% | -23.7% |
| December 31, 2023 | $30.56M | +54.5% | +60.2% |
- Orchestra BioMed Holdings, Inc. showed an increase of +55.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Orchestra BioMed Holdings, Inc.’s cash and equivalents has grown by 1611.5% (from $2.03 million to $34.69 million).
- The most recent figure is from Orchestra BioMed Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: